Invest $2.2 million! The pharmaceutical company will be in Singapore for another city

Recently, according to biomedical media FierePharma, Catalent plans to invest $2.
2 million in Singapore's next city to expand its clinical supply facilities
.

This round of investment will provide an additional 31,000 square feet, which equates to a 20% increase in floor space
.

It will allow the addition of 35 ultra-low temperature freezers
.

Catalent said that as capacity increases, the site will enhance its specialized secondary packaging capabilities for ULT products, enabling it to support a wider range of packaging activities
.

It will also be able to handle more biopharmaceuticals and advanced products, such as mRNA vaccines, as well as cell and gene therapies
.

Publicly available, Catalent is a company dedicated to delivering technology, development and manufacturing solutions for pharmaceuticals, biologics, cell and gene therapies, and consumer health products, with four divisions, including SoftGel and Oral Technologies, Biologics, Oral and Specialist Delivery, and Clinical Supply Services
.

In the Chinese market, Catalent established china's first clinical supply center in March 2013, naming its Chinese company
"Catalent".

Previously, Catalent's global clinical supply network has covered North America, Europe and Asia (Japan, Singapore, etc.
), and its "end-to-end" clinical supply services have been officially implemented in China, accelerating the service process in the Asia-Pacific region and strengthening the cold chain system and special supplies management capabilities
.

In order to meet the growing demand in China and the Asia-Pacific region, Catalent established the Cantel Tangzhen Clinical Supply Center
in Pudong, Shanghai in 2019.

It is also the second clinical supply center
in China.

It is understood that the clinical supply center of Kangtelent Tangzhen and the clinical supply center of Waigaoqiao are combined in terms of facilities, further integrating the global supply network and playing the role of
"1+1>2".

The newly established Kangtelant Tangzhen Clinical Supply Center can help domestic and foreign clinical trial bidding enterprises improve the speed and efficiency of clinical trial supply, better link domestic and foreign clinical trial centers, and provide more flexible clinical research supply solutions
.

In recent years, with the rapid development and acceleration of change in the global pharmaceutical market, Catalent has made frequent
moves.

In July 2022, the company announced blockbuster plans to reduce the division from four to two, with one focused on biologics and one focused on pharmaceuticals and consumer health
.

Earlier, Catalent has been actively engaged in related acquisitions and divestitures
.

For example, in March 2021, the company acquired the manufacturing and packaging assets of Delphi Genetics SA (gene cloning and protein expression of bacteria) and Acorda Therapeutics, Inc.
(Neurotherapy Company); In August 2021, rheinCell Therapeutics GmbH (Cell Therapy CDMO) was acquired, followed by Bettera Holdings, LLC (Nutritional Supplement)
in October of that year.

Catalent also sold
Catalent USA Woodstock, Inc.
and certain related assets.

In addition, as the environment changes, Catalent has accelerated and strengthened certain capital improvement programs to expand the ability to produce APIs and pharmaceutical products for protein biologics and cell and gene therapies, particularly in Bloomington, Indiana, and Anani, Italy, as well as commercial-scale viral vector manufacturing facilities
in Maryland.

According to the Q4 2022 financial report, Catalent achieved revenue of $1.
313 billion, compared with $1.
188 billion in the previous value and $1.
33 billion in expected value, which was 1.
28% lower than market expectations; Earnings per share were $1.
19 compared to $1.
16 prior and expected at $1.
15, beating market expectations by 3.
48 percent
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.